Author Archives: donttradeourlivesaway

Supreme Court denies Teva stay in Copaxone patent fight

Source: Reuters (Reuters) – U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva’s top-selling … Continue reading

Posted in patent infringement | Leave a comment

Govt prepares to battle US pressure on patents

  Source: Business Standard Top officials meet amid apprehension of sanctions under US law; decide to take Washington to the World Trade Organization if such action taken    Nayanima Basu  |  April 22, 2014 The government held a high-level meeting … Continue reading

Posted in Indian Patent Law, IP Rights, TRIPS, TRIPS flexibilities, US pressure on India | Leave a comment

Gilead to brief US Congress on its pricing strategy for new oral Hep-C drug

US Congress demands briefing from Gilead on its pricing strategy for Sofosbuvir (Sovaldi)- new oral drug for Hep-C treatment for which it recently received marketing approval in US. The Committee of Energy and Commerce, House of Congress asked for providing … Continue reading

Posted in Drug Pricing, Hepatitis - C | Tagged , | Leave a comment

Recent developments on Hep-C treatment and access

Recently, there have been two key developments in the area of Hep-C treatment– firstly the release of the first ever WHO guidelines for screening, care and treatment of persons infected with HCV and secondly the specific discussion on generic production … Continue reading

Posted in Hepatitis - C, patent | Leave a comment

32 Members of US House of Representatives ask USTR to sanction Canada for not granting patents on drugs

Source: KEI Submitted by James Love,, 11. April 2014 A letter dated April 10, 2014 signed by a bipartisan group of 32 members of the House of Representatives, have asked USTR to elevate Canada to the Special 301 “priority watch list,” for “violation … Continue reading

Posted in USTR 301 report | Leave a comment

Eli Lilly vs. Canada: The Patent War Moves to Washington

Angered by Canadian court decisions that invalidated patents on two drugs, Eli Lilly is striking back by urging Washington to pressure Canada to change its stance toward intellectual property. Its efforts underscore growing frustration the pharmaceutical industry has toward some foreign governments … Continue reading

Posted in Investment treaties, investor state dispute, patent, USTR 301 report | Leave a comment

UK court overturns patents on Roche’s Herceptin

Source: Pharma Times 15 March 2014 The likelihood of a biosimilar version of Herceptin reaching the UK marketin the next few months has increased dramatically after the High Courtoverturned two key patents on Roche’s breast cancer blockbuster.The ruling, which stated … Continue reading

Posted in biosimilars, patent | Leave a comment

International Liver Conference: activists demand affordable hepatitis C treatment

Source: Hep Coalition 15 April 2014 International Liver Conference: activists demand affordable hepatitis C treatment Pills cost pennies, greed costs lives. As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise … Continue reading

Posted in access to medicines, Hepatitis - C | Leave a comment

Natco seeks to block Gilead’s hepatitis C drug patent in India: source

Source: Reuters 11 April 2014 (Reuters) – India’s Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said. … Continue reading

Posted in Generic drug, Hepatitis - C, patent, Patent Opposition | Tagged , , | Leave a comment

A matter of life and death

Source: Kashmir Times 11 April 2014 If you or some family members or friends suffer from cancer, hepatitis, AIDs, asthma or other serious ailments, it’s worth your while to follow the Trans-Pacific Partnership Agreement (TPPA) negotiations. It’s really a matter of … Continue reading

Posted in Compulsory Licensing, data exclusivity, TPPA, TRIPS plus | Leave a comment